The Roles of ApoC-III on the Metabolism of Triglyceride-Rich Lipoproteins in Humans

Show full item record



Permalink

http://hdl.handle.net/10138/319452

Citation

Boren , J , Packard , C J & Taskinen , M-R 2020 , ' The Roles of ApoC-III on the Metabolism of Triglyceride-Rich Lipoproteins in Humans ' , Frontiers in Endocrinology , vol. 11 , 474 . https://doi.org/10.3389/fendo.2020.00474

Title: The Roles of ApoC-III on the Metabolism of Triglyceride-Rich Lipoproteins in Humans
Author: Boren, Jan; Packard, Chris J.; Taskinen, Marja-Riitta
Other contributor: University of Helsinki, HUS Heart and Lung Center




Date: 2020-07-28
Language: eng
Number of pages: 10
Belongs to series: Frontiers in Endocrinology
ISSN: 1664-2392
DOI: https://doi.org/10.3389/fendo.2020.00474
URI: http://hdl.handle.net/10138/319452
Abstract: Cardiovascular disease (CVD) is the leading cause of death globally. It is well-established based on evidence accrued during the last three decades that high plasma concentrations of cholesterol-rich atherogenic lipoproteins are causatively linked to CVD, and that lowering these reduces atherosclerotic cardiovascular events in humans (1-9). Historically, most attention has been on low-density lipoproteins (LDL) since these are the most abundant atherogenic lipoproteins in the circulation, and thus the main carrier of cholesterol into the artery wall. However, with the rise of obesity and insulin resistance in many populations, there is increasing interest in the role of triglyceride-rich lipoproteins (TRLs) and their metabolic remnants, with accumulating evidence showing they too are causatively linked to CVD. Plasma triglyceride, measured either in the fasting or non-fasting state, is a useful index of the abundance of TRLs and recent research into the biology and genetics of triglyceride heritability has provided new insight into the causal relationship of TRLs with CVD. Of the genetic factors known to influence plasma triglyceride levels variation inAPOC3- the gene for apolipoprotein (apo) C-III - has emerged as being particularly important as a regulator of triglyceride transport and a novel therapeutic target to reduce dyslipidaemia and CVD risk (10).
Subject: apoC-III
triglycerides
lipoproteins
lipids
cardiovascular disease
APOLIPOPROTEIN-C-III
RECEPTOR-ALPHA/GAMMA AGONIST
HIGH-DENSITY-LIPOPROTEIN
OF-FUNCTION MUTATIONS
LIPID-BINDING
ATHEROGENIC LIPOPROTEINS
CARDIOVASCULAR RISK
INSULIN-RESISTANCE
PROTEOGLYCAN-BINDING
HYPOLIPIDEMIC ACTION
3121 General medicine, internal medicine and other clinical medicine
Rights:


Files in this item

Total number of downloads: Loading...

Files Size Format View
fendo_11_00474.pdf 603.7Kb PDF View/Open

This item appears in the following Collection(s)

Show full item record